Related Experiment Video

Updated: Aug 7, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.3K

Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer

Ioannis A Voutsadakis1,2

  • 1Algoma District Cancer Program, Sault Area Hospital, 750 Great Northern Road, Sault Ste. Marie, ON P6B 0A8, Canada.

Medicina (Kaunas, Lithuania)
|September 28, 2021
PubMed

Insights

Amplification of chromosome 20q11.21 genes in colorectal cancer cell lines correlates with specific drug sensitivities and gene dependencies. This finding may guide the development of targeted therapies for this cancer subtype.

Area of Science:

  • Genomics
  • Cancer Biology
  • Pharmacology

Background:

  • The 20q11.21 chromosomal locus is frequently amplified in colorectal cancer (CRC), affecting 8-9% of patients.
  • Several candidate oncogenes reside within this amplified region, but their therapeutic relevance in CRC is not well understood.
  • Understanding the functional consequences of 20q11.21 amplification is crucial for developing targeted CRC treatments.

Purpose of the Study:

  • To investigate the prevalence of 20q11.21 gene amplifications in colorectal cancer cell line models.
  • To correlate these amplifications with gene essentiality and drug sensitivity profiles.
  • To identify potential therapeutic strategies for CRC with 20q11.21 amplifications.

Main Methods:

  • Analysis of colorectal cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE) for 20q11.21 amplifications.
  • Correlation analysis of amplifications with gene essentiality data from CRISPR and RNAi screens.
  • Survey of drug sensitivity databases to identify associations between amplifications and drug responses.

Main Results:

  • Nineteen percent (12/63) of CRC cell lines in the CCLE exhibit 20q11.21 amplifications, involving genes such as ASXL1, DNMT3B, BCL2L1, TPX2, KIF3B, and POFUT1.
  • Amplified cell lines show variable mRNA overexpression and are sensitive to tyrosine kinase inhibitors but resistant to microtubule-targeting chemotherapy.
  • CRISPR/RNAi screens identified recurrent gene dependencies, including YAP1 and JUP, in addition to known CRC drivers like beta-catenin and KRAS.

Conclusions:

  • Colorectal cancer cell lines with 20q11.21 amplifications exhibit distinct gene dependencies and drug sensitivity/resistance profiles.
  • These in vitro findings provide a basis for developing novel, targeted therapies for this specific CRC subtype.
  • This approach can uncover genetic lesions conferring synthetic lethality, paving the way for new drug development strategies.
Keywords:
cancer therapeuticsdatabasesdrug developmentpreclinical candidatestargeted therapies

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.0K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...